Clarivate’s Strategic Pivot: Selling Life Sciences to Power an AI-First Future
LS&H divestiture sharpens focus on A&G and IP; organic ACV and margins improve, but execution risks remain
CLVT · Earnings Call · 2026-07-29
A Strategic Inflection Point
Clarivate’s Q2 2026 earnings call was less about quarterly numbers and more about a decisive strategic pivot. The headline is the agreement to sell the Life Sciences & Healthcare (LS&H) segment to Altaris, a move that refocuses the company on its two remaining segments: Academia & Government (A&G) and Intellectual Property (IP). As CEO Matti Shem Tov put it, "We are delivering on our commitment and now we have the building blocks in place to accelerate organic growth."
We are moving forward with urgency. Our progress is clear. We are investing wisely, operating with more discipline, and directing resources towards the highest value growth opportunities.
The LS&H divestiture is not just a portfolio trim; it improves the quality of revenue. Pro forma recurring revenue mix rises from 89% to approximately 92%, enhancing predictability and cash-flow visibility. The proceeds will be used to reduce debt, extending average maturity and strengthening the balance sheet. Jonathan Collins, the outgoing CFO, confirmed in the Q&A that the process is on track: "We expect this to close before the end of the year." This is a clean exit from a segment that had the highest transactional mix and the weakest growth profile, allowing management to concentrate on the AI-driven opportunities in A&G and IP.
AI Innovation and Product Momentum
The call doubled down on AI as the engine for organic growth. Two new agentic AI products were introduced: Nexus Connect, an AI-native gateway that connects university resources to ChatGPT and Claude, and IP-1, a unified AI platform for IP professionals. These products are designed to embed Clarivate’s proprietary data into customer workflows, creating new revenue streams. Matti Shem Tov emphasized: "We see the AI enablement of our existing product. It is a source for revenue for new logos, new products, new returns, improving your retention, and I think also to allow us to have some AI-specific pricing for new products."
The early traction is visible: Web of Science Research Intelligence has already generated a multimillion-dollar ACV pipeline with 77 paying customers. The company is also pursuing ecosystem integrations, such as embedding its data into Anthropic’s enterprise offerings, turning LLMs into sales agents. This Agentic AI push is complemented by a renewed focus on sales execution and retention. In the prior quarter, management had already signaled this direction. On the February call, Jonathan Collins noted, "Yes. Thanks, Toni. More broadly, for example, within the A&G segment, as Matti highlighted, the pricing of the subscriptions is based on the size of the institution..." (9073640907538705783) — a reminder that the pricing model remains strong.
Financial Discipline and Balance Sheet
Financially, the quarter showed steady execution. Organic ACV growth improved to 1.5%, and adjusted EBITDA margin expanded to over 42%. Jonathan Collins explained, "disciplined cost management allowed us to maintain our adjusted EBITDA margin over the same period last year despite the revenue decline." Free cash flow was $44 million, down slightly due to working capital timing, but the company repurchased $75 million of bonds, reducing first-half debt by $218 million. With LS&H proceeds, total debt reduction is expected to reach about $900 million this year.
The balance sheet remains heavily levered, with Effective Net Cash at -$4.0 billion in the latest quarter. However, the trend is improving as deleveraging continues. Gross margin has also been creeping up, reaching 67.2% in Q1 2026, a sign of the shift toward higher-margin subscription revenue.
Looking ahead, full-year guidance remains largely intact, with adjusted EBITDA around $1 billion and EPS growth of about 9%. Management expects sequential improvement in recurring organic growth in the second half, driven by record retention and new product adoption. The path forward is not without risk — the stock has fallen over 90% from its peak, and the company is digesting a major divestiture and a CFO transition. But the strategic clarity and AI-focused innovation agenda suggest a credible turnaround story. As Matti Shem Tov asserted, "We are seeing more market validation for our IP innovation." The prior year’s sales discipline is paying off, as he recalled: "I think we've taken away a lot of hassle from the sales organization. We are very, very focused these day, subscription, reoccurring renewal price, bringing back new business." (276172281823066341) — a testament to the consistency of the strategy.